San Diego, August 25, 2025 — BiotechReporter.news — iBio, Inc. (Nasdaq: IBIO) announced the closing of its previously announced underwritten public offering, securing initial gross proceeds of approximately $50 million. The offering included pre-funded warrants to purchase 71,540,000 shares of iBio’s common stock, and Series G and H warrants.
If all Series G and H warrants are exercised for cash, iBio anticipates receiving an additional $50 million in gross proceeds, bringing the potential total to $100 million. The financing was led by Balyasny Asset Management, with participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.
iBio intends to allocate the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, continue progress on other preclinical pipeline assets, and fund working capital and general corporate purposes.
Leerink Partners acted as the lead bookrunner. LifeSci Capital and Oppenheimer & Co. acted as bookrunning managers. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as financial advisor to iBio.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
David Schull, Russo Partners, LLC
David.schull@russopartnersllc.com
(646) 942-5604
Source: iBio, Inc.
